Quality of life in japanese patients with dysmenorrhea treated with ethinylestradiol 20 μg/drospirenone 3 mg in a real-world setting: An observational study

Mikio Momoeda, Sayako Akiyama, Kota Tanaka, Yoshimi Suzukamo

Research output: Contribution to journalArticle

Abstract

Background: Dysmenorrhea affects approximately 80% of women in Japan and has a negative impact on health-related quality of life (HRQoL). Low-dose estrogen/progestin combined oral contraceptives have been shown to reduce the severity of dysmenorrhea symptoms. This study characterized HRQoL in Japanese women with dysmenorrhea before and after ethinylestradiol/drospirenone (EE/DRSP) treatment. Methods: This prospective, observational study recruited 531 patients, of which 186 were evaluated after treatment with EE 20 μg/DRSP 3 mg for dysmenorrhea in a 24/4 cyclic regimen. The primary endpoints were mean baseline and post-treatment 36-Item Short-Form Health Survey version 2.0 (SF-36v2) scores for study patients compared with the general female population of Japan (calculated using norm-based scoring), and mean changes in study patient SF-36v2 scores between baseline and 6 to 8 treatment cycles. Results: Compared with Japanese norms, women with dysmenorrhea had lower pre-treat-ment SF-36v2 scores, except for the physical functioning domain. After 6–8 cycles of EE/ DRSP treatment, all 8 SF-36v2 domain scores were significantly higher than baseline. The greatest improvements were observed in bodily pain and social functioning (mean change [standard deviation (SD)]: physical functioning: 1.4 [5.7], role physical: 3.2 [8.1], bodily pain: 7.8 [10.0], general health: 3.0 [7.0], vitality: 2.7 [8.1], social functioning: 3.5 [9.8], role emotional: 3.3 [9.2], and mental health: 3.0 [7.3]; p< 0.001 for all). Compared with the Japanese general population, study patients’ post-treatment scores were significantly higher for the general health domain (p= 0.008) and physical summary scores (p= 0.033). Conclusion: Dysmenorrhea has a profound impact on all aspects of functioning and well-being. This study, conducted in a real-world setting, found that physical, social, and mental HRQoL improved significantly after a cyclic regimen of EE/DRSP in Japanese patients with dysmenorrhea. This regimen may have the potential to provide an effective option to improve patient HRQoL. Trial Registration: Study sample was drawn from patients enrolled in a post-marketing surveillance study, registered June 20, 2011 (NCT 01375998).

Original languageEnglish
Pages (from-to)327-338
Number of pages12
JournalInternational Journal of Women's Health
Volume12
DOIs
Publication statusPublished - 2020

Keywords

  • Dysmenorrhea
  • Ethinylestradiol/drospirenone
  • Japan
  • Patient-reported outcomes
  • Quality of life
  • SF-36

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology
  • Maternity and Midwifery

Fingerprint Dive into the research topics of 'Quality of life in japanese patients with dysmenorrhea treated with ethinylestradiol 20 μg/drospirenone 3 mg in a real-world setting: An observational study'. Together they form a unique fingerprint.

  • Cite this